China Pharma Holdings (CPHI) Research & Development (2016 - 2025)
Historic Research & Development for China Pharma Holdings (CPHI) over the last 13 years, with Q3 2025 value amounting to $40321.0.
- China Pharma Holdings' Research & Development fell 5397.67% to $40321.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $91407.0, marking a year-over-year decrease of 7878.93%. This contributed to the annual value of $283942.0 for FY2024, which is 1826.97% up from last year.
- Latest data reveals that China Pharma Holdings reported Research & Development of $40321.0 as of Q3 2025, which was down 5397.67% from $20952.0 recorded in Q2 2025.
- In the past 5 years, China Pharma Holdings' Research & Development registered a high of $190086.0 during Q1 2021, and its lowest value of $547.0 during Q4 2024.
- Moreover, its 5-year median value for Research & Development was $40321.0 (2025), whereas its average is $58931.8.
- Examining YoY changes over the last 5 years, China Pharma Holdings' Research & Development showed a top increase of 59202.0% in 2024 and a maximum decrease of 9962.93% in 2024.
- Quarter analysis of 5 years shows China Pharma Holdings' Research & Development stood at $54048.0 in 2021, then crashed by 48.2% to $27999.0 in 2022, then surged by 426.99% to $147552.0 in 2023, then plummeted by 99.63% to $547.0 in 2024, then skyrocketed by 7271.3% to $40321.0 in 2025.
- Its Research & Development stands at $40321.0 for Q3 2025, versus $20952.0 for Q2 2025 and $29587.0 for Q1 2025.